From brighty119 Jun 2023 09:16
It's also worth remembering that ABDX's founder and Chairman sold his last business, Cozart, to Concateno for £64.4mm in cash. i.e. We have a strong and experienced management team at ABDX. In our sector big bucks are paid to acquire smaller rivals. You only have to look at the sale in 2021 of Wales based diagnostics and life sciences business BBI, which was sold for £400 million (x26 of our current mcap). Remember, we IPO'd 18 months ago at £100m (x 7 of our current mcap). The testing industry is growing exponentially in the UK and worldwide. The IPO enabled investment in the business and ABDX is on the launch pad ready to produce hundreds of millions of various tests. It is clear that there are lots of positive reasons to invest in ABDX moving forward. Salistick, the UK's first ever saliva-based pregnancy test is just one of many opportunities for ABDX to carve out market share. We should be back up to the placing price of 25p a share soon but in 18-24 months ABDX could be back at its ipo price of 96p a share if things start to pan out as many of us expect....
Good luck, Brighty